Allen Yang | Senior Vice President and Chief Medical Officer

Allen Yang, Senior Vice President and Chief Medical Officer, Xencor

Dr. Yang is responsible for leading clinical development strategy and overseeing clinical operations for Xencor’s portfolio of XmAb® drug candidates. Prior to joining Xencor in 2019, he served as senior vice president, head of clinical development and acting chief medical officer at Jazz Pharmaceuticals. Before assuming this role at Jazz, Dr. Yang was the therapeutic area head for hematology and oncology, assembling its clinical development team and overseeing several oncology products, including Erwinaze®, Defitelio® and Vyxeos®. Prior to Jazz, Dr. Yang led clinical development and clinical operations groups at Spectrum Pharmaceuticals, where he was vice president of clinical research. Previously, he held several roles of increasing responsibility at Amgen, including those of global development leader for Aranesp® in oncology and clinical research medical director for Blincyto®, the first bispecific antibody approved by the FDA. Before transitioning to the biopharmaceutical industry, Dr. Yang practiced medicine for several years as an academic oncologist at the University of Southern California, where he led a translational cancer research laboratory. Dr. Yang earned a B.A. in molecular biology from the University of California, Berkeley, and a Ph.D. in biochemistry and an M.D. from the University of Southern California. He completed his medical oncology fellowship at the MD Anderson Cancer Center.


Error processing SSI file

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall